Consensus expectations for Veeva's fourth quarter are $810.95 million in revenue and $1.92 in non-GAAP EPS, with the stock trading at approximately $182.88 against an average analyst price target of $300.55.
Investors are primarily focused on the multi-year Vault CRM migration as Veeva transitions its customer base away from the Salesforce platform to its proprietary infrastructure.
While management expects to retain the vast majority of top-tier biopharma clients, intensifying competition from Salesforce’s Life Sciences Cloud continues to weigh on sentiment. Simultaneously, analysts are monitoring the company's successful diversification as R&D Solutions is projected to overtake Commercial Solutions as the primary driver of subscription growth.